Browsing by Author "Mauri, Davide"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- COVID-19 vaccinations: summary guidance for Cancer patients in 28Languages: breaking barriers to Cancer patient InformationPublication . Mauri, Davide; Kamposioras, Konstantinos; Tsali, Lampriani; Dambrosio, Mario; De Bari, Berardino; Hindi, Nadia; Salembier, Carl; Nixon, Joanna; Dimitrios, Tzachanis; Alongi, Flippo; Hameed, Hassan; Valachis, Antonios; Papadimitriou, Konstantinos; Corradini, Stefanie; Popovic, Lazar; Kopecky, Jindrich; Rodriguez, Andres; Antunac, Katarina; Yi, Junlin; Lovey, Jozsef; Strojan, Primoz; Saraireh, Haytham; Røtterud, Ranveig; Chojnacka, Marzanna; Olalla, Santa Cruz; Chilingirova, Natalia; De Mello, Ramon Andrade; Amaral, Giovanna Araujo; Arbabi, Farsid; Vidra, Radu; Rapushi, Erjeta; Takeuchi, Dan; Christopoulos, Chirstos; Ivanova, Irina; Djan, Igor; Petricevic, Branka; Cellini, Francesco; Mihaylova, Iglika; Plavetic, Natalija Dedic; Kuhar, Cvetka Grašič; Takeuchi, Elena; Kountourakis, Pantelis; Ntellas, Panagiotis; Gazouli, Ioanna; Gkoura, Stefania; Yuce, Salih; ER, Özlem; Yasmina, Chait; Kumaran, Gireesh; Spahiu, Orges; Yusuf, Aasim; Gono, Paulina; Apostolidis, Kathi; Tolia, MariaBackground: Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the English language only is a major limit for recommendations' delivery and their application in the world's population and generates information inequalities across the different populations. Methods: Most of the available COVID-19 vaccination guidance for cancer patients was screened and scrutinized by the European Cancer Patients Coalition (ECPC) and an international oncology panel of 52 physicians from 33 countries. Results: A summary guidance was developed and provided in 28 languages in order to reach more than 70 percent of the global population. Conclusion: Language barrier and e-guidance availability in the native language are the most important barriers when communicating with patients. E-guidance availability in various native languages should be considered a major priority by international medical and health organizations that are communicating with patients at the global level.
- Cutaneous soft tissue sarcomas: survival-related factorsPublication . Gkantaifi, Areti; Diamantis, Alexandros; Mauri, Davide; Nixon, Ioanna; Kyriazoglou, Anastassios; Baloyiannis, Ioannis; Tsoukalas, Nikolaos; Charalampakis, Nikolaos; Schizas, Dimitrios; Cuccia, Francesco; Alongi, Filippo; De Mello, Ramon Andrade; Iliadis, George; Kamposioras, Konstantinos; Mazonakis, Michalis; Tolia, MariaCutaneous sarcomas are a heterogeneous group of rare mesenchymal neoplasms representing less than 1% of malignant tumors. Histology report remains the cornerstone for the diagnosis of these tumors. The most important clinicopathologic parameters related to prognosis include larger tumor size, high mitotic index, head and neck location, p53 mutations, depth of infiltration and histological grade, vascular and perineural invasion as well as the surgical margins status. Applying advanced biopsy techniques might offer more precise assessment of surgical margins, which constitutes a significant precondition for the management of these tumors. The management of cutaneous soft tissue sarcomas requires a multidisciplinary approach. Surgery remains the standard treatment, nonetheless adjuvant therapy may be required, consisting of radiotherapy, chemotherapy, and molecular targeted therapies to improve treatment outcomes. The role of molecular profiling in the treatment of uncontrolled disease is promising, but it may be offered to a relatively small proportion of patients and its use is still considered experimental in this setting. Due to the rarity of the disease, there is a need for knowledge and experience to be shared, pooled, organized and rationalized so that recent developments in medical science can have a major impact on the disease course. Multicenter clinical trials are needed to improve the care of patients with cutaneous sarcomas.
- Synthesis of recommendations from 25 countries and 31 oncology societies: how to navigate through Covid-19 labyrinthPublication . Kamposioras, Konstantinos; Mauri, Davide; Papadimitriou, Konstantinos; Anthoney, Alan; Hindi, Nadia; Petricevic, Branka; Dambrosio, Mario; Valachis, Antonis; Kountourakis, Pantelis; Kopecky, Jindrich; Kuhar, Cvetka Grašič; Popovic, Lazar; Chilingirova, Nataliya P.; Zarkavelis, George; De Mello, Ramon Andrade; Plavetić, Natalija Dedić; Christopoulos, Christos; Mostert, Bianca; Goffin, John R.; Tzachanis, Dimitiros; Saraireh, Haytham Hamed; Ma, Fei; Pavese, Ida; Tolia, MariaIntroduction Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak. Methods We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies. Results By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis. Conclusions In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.